Nasdaq - Delayed Quote USD

Fidelity Disruptive Medicine Fund (FMEDX)

11.28
-0.02
(-0.18%)
At close: January 23 at 8:01:16 PM EST

Performance Overview

Morningstar Return Rating --
YTD Return 4.82%
5y Average Return 0.00%
Number of Years Up 1
Number of Years Down 1
Best 1Y Total Return (Jun 8, 2023) 10.99%
Worst 1Y Total Return (Jun 8, 2023) --
Best 3Y Total Return 10.99%
Worst 3Y Total Return --

Trailing Returns (%) Vs. Benchmarks

Monthly Total Returns
FMEDX
Category
YTD
4.82%
7.95%
1-Month
-2.42%
4.81%
3-Month
5.21%
7.18%
1-Year
11.88%
30.16%
3-Year
1.19%
16.10%
5-Year
0.00%
15.71%
10-Year
0.00%
15.27%
Last Bull Market
25.31%
23.06%
Last Bear Market
-16.20%
-13.88%

Annual Total Return (%) History

Year
FMEDX
Category
2023
--
--
2022
-21.71%
--
2021
10.99%
--
2020
--
27.63%

Past Quarterly Returns

YearQ1Q2Q3Q4
2023 1.95% -- -- --
2022 -13.51% -16.20% 1.20% 6.73%
2021 -0.08% 9.27% 0.99% 0.66%
2020 5.27% 7.10% -- --

Rank in Category (By Total Return)

YTD 22
1-Month 54
3-Month 29
1-Year 18
3-Year 73
5-Year --

Load Adjusted Returns

1-Year 10.34%
3-Year 0.35%
5-Year --
10-Year --

Performance & Risk

YTD Return 4.82%
5y Average Return 0.00%
Rank in Category (ytd) 22
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.78
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Fidelity Investments
Net Assets 43.22M
YTD Return 4.82%
Yield 0.00%
Morningstar Rating
Inception Date Apr 16, 2020

Fund Summary

Normally the fund invests at least 80% of assets in securities of disruptive medicine companies. Normally it invests primarily in equity securities. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness. The fund is non-diversified.

Related Tickers